人間の心不全における誘導性酸化窒素合成酵素の発現
G A Haywood1, P S Tsao, H E von der Leyen
1Department of Cardiological Sciences, St. George's Hospital, London, UK.
Circulation
|March 15, 1996
まとめ
誘導性酸化窒素合成酵素 (iNOS) は,心不全患者の心臓細胞で発現し,膨張性心筋病や缺血性心疾患などの状態におけるその役割を示唆しています.
科学分野:
- 心血管科学 心血管科学
- 分子生物学は分子生物学である.
- 病理生理学 病理生理学とは
背景:
- 酸化窒素 (NO) 合成の変化は,心不全に関連しています.
- 内皮のNOS (eNOS) は研究されているが,誘導性NOS (iNOS) の役割は不明である.
研究 の 目的:
- 人間の心不全における誘導性酸化窒素合成酵素 (iNOS) の発現と重要性を調査する.
主な方法:
- 心不全患者,ドナーハート,対照群からの心室筋筋内におけるiNOS mRNAとタンパク質発現を分析した.
- リバーストランスクリプション-ポリメラーゼ連鎖反応 (RT-PCR) と免疫ヒストケミストリーを利用した.
- ウエスタン・ブロット分析により,iNOSタンパク質濃度が確認されました.
主要な成果:
- iNOSは,心不全患者の71%で発現したが,対照群では発現しなかった (P<.0001).
- iNOS mRNAとタンパク質は,心不全の全4室の心筋細胞で検出されました.
- 表情は,心房不全のマーカーである心房ナトリウレチンペプチド (ANP) と相関する.
結論:
- 誘導性NOS (iNOS) は,衰弱するヒト心筋細胞で表されます.
- iNOSは,膨張性心筋病変 (DCM),缺血性心臓病 (IHD),弁性心臓病 (VHD) の病理生理学に役割を果たす可能性があります.
関連する概念動画
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...